MEDIAL ROTATION KNEE SYSTEM

K020214 · Engineering Consulting Services, Inc. · JWH · Feb 26, 2002 · Orthopedic

Device Facts

Record IDK020214
Device NameMEDIAL ROTATION KNEE SYSTEM
ApplicantEngineering Consulting Services, Inc.
Product CodeJWH · Orthopedic
Decision DateFeb 26, 2002
DecisionSESE
Submission TypeTraditional
Regulation21 CFR 888.3560
Device ClassClass 2
AttributesTherapeutic

Indications for Use

The Medial Rotation Knee™ System is intended for single-use cemented implantation for use in total knee arthroplasty surgery for the reduction in relief of pain and/or improved knee function in skeletally mature patients with the following conditions: • Non-inflammatory degenerative joint disease resulting from osteoarthritis, traumatic arthritis, or avascular necrosis • Inflammatory degenerative joint disease including rheumatoid arthritis • Correction of varus, valgus, or post traumatic deformity • Correction or revision of unsuccessful osteotomy or arthrodesis • Revision procedures where other treatments or devices have failed • Treatment of fractures that are unmanageable using other techniques

Device Story

Medial Rotation Knee™ System is a semi-constrained total knee prosthesis; primary and revision use. Components include CoCr femoral component; stemmed CoCr metal-backed polyethylene tibial component; all-poly patella component. Designed for cemented implantation. Congruency in tibiofemoral and patellofemoral articulation facilitates natural knee movement and range of motion while minimizing polyethylene wear. Used by orthopedic surgeons in clinical/OR settings to replace damaged knee joints; provides pain relief and functional restoration for patients with degenerative joint disease or deformity.

Clinical Evidence

The device is supported by over 30 years of proven clinical use. No new clinical study data was required for this 510(k) submission.

Technological Characteristics

Semi-constrained, cemented knee prosthesis. Materials: Cobalt-Chromium (CoCr) femoral and tibial components, polyethylene tibial insert and patella component. Design features include stemmed metal-backed tibial component and congruent articulation surfaces. Intended for single-use.

Indications for Use

Indicated for skeletally mature patients requiring total knee arthroplasty for pain relief or improved function due to osteoarthritis, traumatic arthritis, avascular necrosis, rheumatoid arthritis, varus/valgus/post-traumatic deformity, failed osteotomy/arthrodesis, or unmanageable fractures.

Regulatory Classification

Identification

A knee joint patellofemorotibial polymer/metal/polymer semi-constrained cemented prosthesis is a device intended to be implanted to replace a knee joint. The device limits translation and rotation in one or more planes via the geometry of its articulating surfaces. It has no linkage across-the-joint. This generic type of device includes prostheses that have a femoral component made of alloys, such as cobalt-chromium-molybdenum, and a tibial component or components and a retropatellar resurfacing component made of ultra-high molecular weight polyethylene. This generic type of device is limited to those prostheses intended for use with bone cement (§ 888.3027).

Predicate Devices

Submission Summary (Full Text)

{0}------------------------------------------------ Finsbury (Instruments) Limited 510(k) for the Medial Rotation Knee January 19, 2002 ge lof Section C: Summary of Safety & Effectiveness ## 510(k) Summary of Safety and Effectiveness SAFE MEDICAL DEVICES ACT OF 1990 SAFE MEDICAL DEVICES ACT OF 1990 | NAME OF FIRM: | Finsbury (Instruments) Limited<br>13 Mole Business Park<br>Randalls Road<br>Leatherhead, Surrey KT22 OBA<br>United Kingdom | |-----------------------------------------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | 510(k) FIRM CONTACT: | Al Lippincott<br>Engineering Consulting Services, Inc.<br>3150 E. 200th St.<br>Prior Lake, MN 55372 | | TRADE NAME: | Medial Rotation Knee™ System | | COMMON NAME: | Knee Prosthesis | | CLASSIFICATION: | Prosthesis, Knee patellofemorotibial, Semi-constrained, Cemented, Polymer/Metal/Polymer per 21CFR, Sec 888.3390 | | DEVICE PRODUCT CODE: | 87JWH | | SUBSTANTIALLY<br>EQUIVALENT: | DePuy, Freeman/Samuelson Total Knee (K830726)<br>Sulzermedica, Mark II Freeman/Samuelson Total Knee System (K853730)<br>Biomet, Freeman/Samuleson Total Knee System (K943025)<br>Wright Medical Technology, Inc., Advance Ultra-Conguent Tibial Insert (K972770)<br>Renaissance Instruments, LLC., FS 1000 Knee System (K991052) | | DEVICE DESCRIPTION: | The Medial Rotation Knee™ System is both a primary and revision total knee system composed of a CoCr Femoral component mating with a stemmed CoCr metal backed polyethylene Tibial and all-poly Patella components. The conguency in tibialfemoral and patellafemoral articulation allow for natural knee movement and ROM while minimizing polyethelene wear. | | INTENDED USE: | The Medial Rotation Knee™ System is intended for single-use cemented implantation for use in total knee arthroplasty surgery for the reduction in relief of pain and/or improved knee function in skeletally mature patients with the following conditions:<br>• Non-inflammatory degenerative joint disease resulting from osteoarthritis, traumatic arthritis, or avascular necrosis<br>• Inflammatory degenerative joint disease including rheumatoid arthritis<br>• Correction of varus, valgus, or post traumatic deformity<br>• Correction or revision of unsuccessful osteotomy or arthrodesis<br>• Revision procedures where other treatments or devices have failed<br>• Treatment of fractures that are unmanageable using other techniques | | BASIS OF SUBSTANTIAL<br>EQUIVALENCY: | The Medial Rotation Knee™ System is substantially equivalent to the many semi- constrained metal/polyethylene total knee systems currently on the market and specifically to the:<br>(1). FS 1000 Knee System from Renaissance Instruments, LLC.,<br>(2). Advance Ultra-Congruent Tibial Insert from Wright Medical Technology, Inc, and<br>(3). Freeman/Samuelson Total Knee System from Biomet, Inc. | | SUMMARY OF SAFETY<br>AND EFFECTIVENESS: | The Medial Rotation Knee™ System is shown to be safe and effective with over 30 years of proven clinical use. | FEB 2 6 2002 K020214 {1}------------------------------------------------ Image /page/1/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo is circular and contains the text "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" around the perimeter. Inside the circle is an abstract symbol that resembles an eagle or bird in flight, composed of three curved lines. Food and Drug Administration 9200 Corporate Boulevard Rockville MD 20850 FEB 2 6 2002 Finsbury (Instruments) Limited c/o Mr. Al Lippincott U.S. Regulatory Representative Engineering Consulting Services, Inc 3150 E. 200m St Prior Lake, Minnesota 55372 Re: K020214 Trade Name: Medial Rotation Knee System Regulation Number: 888.3390 Regulation Name: Knee patellofemorotbibial polymer/metal/polymer semiconstrained cemented prosthesis Regulatory Class: II Product Code: JWH Dated: January 19, 2002 Received: January 22, 2002 Dear Mr. Lippincott: We have reviewed your Section 510(k) premarket notification of intent to market the device we nave reviewed your becamed the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate for use sured in the encreate) to togally to togally with Medical Device Amendments, or to conimered proc to Hay 20, 2017, in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of I ho general ocharels proving practice, labeling, and prohibitions against misbranding and adulteration. If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it If your device is olassinod (500 a00 v) als. Existing major regulations affecting your device can may be subject to such additional controls. Existing major regulation of t be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register. Please be advised that FDA's issuance of a substantial equivalence determination does not mean r lease be advisou that I Drivision that your device complies with other requirements of the Act that I Dri has made a sold regulations administered by other Federal agencies. You must or any I ederal statutes and registements, including, but not limited to: registration and listing (21 compy with an all the 110 0 1 quirt 801); good manufacturing practice requirements as set Of K Part 6077, abouting (21 CFR Part 820); and if applicable, the electronic form in the quality of realist (Sections 531-542 of the Act); 21 CFR 1000-1050. {2}------------------------------------------------ Page 2 - Mr. Al Lippincott This letter will allow you to begin marketing your device as described in your Section 510(k) I his letter will anow you to begin manketing your as warence of your device to a legally premarket notification. The PDA midning of backannal open device and thus, permits your device to proceed to the market. If you desire specific advice for your device on our labeling regulation (21 CFR Part 801 and II you desire specific advice to: your worth devices), please contact the Office of additionally 21 CFR Fall 809.10 for in Viato Charlestions on the promotion and advertising of Compliance at (301) 594-4637. Tidataonally, Nance at (301) 594-4639. Also, please note the your device, picase comate and Other of exerce to premarket notification™ (21CFR Part 807.97). Other general information on your responsibilities under the Act may be obtained from the Other general information on your responsional and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 443-6597 or at its Internet address http://www.fda.gov/cdrh/dsma/dsmamain.html Sincerely yours, Sincerely, K. Mark M. Milliman Celia M. Witten, Ph.D., M.D. Director Division of General, Restorative and Neurological Devices Office of Device Evaluation Center for Devices and Radiological Health Enclosure {3}------------------------------------------------ Image /page/3/Picture/0 description: The image shows the logo for Finsbury Instruments. The logo consists of a stylized letter "F" inside of a circle. Below the circle are the words "FINSBURY" in a larger font and "INSTRUMENTS" in a smaller font. page lot 510(k) NUMBER: Ko20214. DEVICE NAME: Medial Rotation Knee™ System ## INDICATIONS FOR USE: The Medial Rotation Knee™ System is intended for single-use 'cemented' imajor and lea The Medial Notation Rhoo - Oyecty surgery for the reduction or relief of pain and/or ior use in a total And artin opides) - still of patients with the following conditions: - Non-inflammatory degenerative joint disease resulting from osteoarthritis, traumatic arthritis, or � avascular necrosis; - Inflammatory degenerative joint disease including rheumatoid arthritis; � - Correction of varus, valgus, or post traumatic deformity; � - Correction or revision of unsuccessful osteotomy or arthrodesis; � - Revision procedures where other treatments or devices have failed; � - Treatment of fractures that are unmanageable using other techniques; � ## (PLEASE DO NOT WRITE BELOW THIS LINE - CONTINUE ON ANOTHER PAGE IF NEEDED) Concurrence of CDRH, Office of Device Evaluation (ODE) Mark A. Wilkinson (Division Sign-Off) Division of Gener of Gene uro! 5100 K020214 Prescription Use OR Over-The-Counter-Use (Per 21 CFR 801.109) (Optional Format 1-2-96) H:\SUPPLIERS\Mr. Al Lippincott USA\Indications for Use 131201VP.doc Registered Office: i 3 Mole Business Park Randalls Road Leatherhead Surrey KT22 OBA United Kingdom Registered in England No. 1394978 VAT No. GB 235 4849 45
Innolitics

Panel 1

/
Ready

Predicate graph will load when search results are available.

Embedding visualization will load when search results are available.

PDF viewer will load when search results are available.

Loading panels...

Select an item from Submissions

Click any panel, subpart, regulation, product code, or device to see details here.

Section Matches

Results will appear here.

Product Code Matches

Results will appear here.

Special Control Matches

Results will appear here.

Loading collections...